Amgen Inc. (AMGN) is waiting for a decision on FDA Approval on XGEVA for additional indication in treatment of castrate-resistant prostate cancer in men

http://www.stockstobuy.org/group/fdaapp ... e=activity

First they should prove treating makes a difference.

Currently, newly approved drugs make a statistical difference but,

is a few months really "worth it".

Statistics and Reality.

Just like Economics. Glad the recovery is going so well